PARK7 and Parkinson disease: Alpha-synuclein protein, leucine-rich repeat kinase 2 (LRRK2), Parkinson disease protein 7 (PARK7), and DJ-1, as well as myocyte-specific enhancer factor 2D protein (MEF2D), which are dysregulated or mutated in Parkinson’s disease, are CMA substrates (Vogiatzi et al., 2008; Yang et al., 2009; Arias and Cuervo, 2011; Cuervo, 2011; Orenstein et al., 2013; Murphy et al., 2015; Alfaro et al., 2018; Kaushik and Cuervo, 2018).